Form D · Biotechnology
Heligenics, Inc.
Las Vegas, NV · CIK 0001833506
Offering snapshot reported Jan 8, 2025 · SEC filing
- Reported sold
- $2.63M Offering amount: $2.63M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Aug 23, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 8, 2025 | Initial | $2,631,775 | No comparison | 8 | SEC filing |
| Aug 23, 2022 | Initial | $2,160,000 | No comparison | 12 | SEC filing |
| Dec 16, 2020 | Initial | $1,180,000 | No comparison | 39 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-534598
Source: Form D, filed Jan 8, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lawrence John Loomis | Director, Executive |
| Martin Schiller | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10530 Discovery Dr
Las Vegas, NV, 89135
Las Vegas, NV, 89135